FDA
-
-
-
-
-
-
-
BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
-
-
-
-
-
-
-
BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
-
-
-
-
-
-
-
BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
-
-
-
-
-
-
-
BriaCell Receives Green-Light from Data Safety Monitoring Board for its Phase 3 Study in Metastatic Breast Cancer
-
-
-
-
-
-
-
BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc.
-
-
-
-
-
-
-
BriaCell Announces Positive Clinical and Quality of Life Data in Advanced Metastatic Breast Cancer at 2022 San Antonio Breast Cancer Symposium®
-
-
-
-
-
-
-
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
-
322,312 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

